China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received clinical clearance from the US Food and Drug Administration (FDA) for its mRNA vaccine candidate, YKYY026, aimed at preventing herpes zoster.
YKYY026: An Innovative mRNA Vaccine with Proprietary Delivery System
YKYY026 is a novel mRNA vaccine that utilizes Youcare Pharma’s proprietary YK-009 cationic lipid LNP delivery system. In pre-clinical studies, YKYY026 demonstrated its ability to stimulate efficient gE specific IgG antibodies, VZV specific binding antibodies, and CD4+ T cell immune responses. The vaccine showed long-lasting immune effects and good safety, marking a significant advancement in the prevention of herpes zoster.
Youcare Pharma’s Robust Pipeline of Nucleic Acid Drugs
Youcare Pharmaceutical is actively advancing its Category 1 drug pipeline, which consists of 10 nucleic acid drugs. Among them, YKY015, an ultra-long effect lipid-lowering small nucleic acid drug, is undergoing a Phase I study in China following clinical approvals in the US and China. Additionally, CT102, an antisense oligonucleotide (ASO) product targeting liver cancer, is being prepared for Phase III trials.-Fineline Info & Tech
